Aortic Valve
Replacement for Aortic Stenosis after Previous Coronary Artery Bypass
Grafting: Could Early Reoperation be Prevented?
Jean Ph. Verhoye, Franceseca Merlicco,
Ibrahim M. Sami, Giangiuseppe Cappabianca, Hervé Lecouls, Hervé Corbineau,
Thierry Langanay, Alain Leguerrier
Department of Thoracic and Cardiovascular
Surgery, University Hospital, Ponchaillou, Rennes, France |
Background and aim of the study: The study aim was to
examine, retrospectively, the risk of accelerated progression of aortic
stenosis (AS) and outcome after aortic valve replacement (AVR) in patients
who had undergone previous coronary artery bypass graft (CABG) surgery.
Methods: Between 1994 and 2004, 81 patients with mild-to-moderate AS at
the time of CABG underwent subsequent AVR. The mean EuroScore was 10.8 ± 1.8.
The population was divided into three subgroups according to the time interval
between AVR and CABG: group A, <5 years (n = 23); group B, 5-10 years
(n = 34); and group C, >10 years (n = 24).
Results: Mean age at the time of CABG was 70 ± 5, 64 ± 6
and 58 ± 5 years in groups A, B, and C, respectively. The peak transvalvular
gradient was £30 mmHg in 65 patients (80.2%), and 30-50 mmHg in 16
(19.7%). Operative mortality after AVR was 16% in the |
overall population (30%, 11.7%, and 8.6% in groups A,
B, and C, respectively). The mean time interval between CABG and AVR
was 8.9 ± 5.2 years. By multivariate analysis, a peak transvalvular
gradient ≥30 mmHg (p = 0.003), moderate calcifications with moderately-to-severely
limited valve motion (p = 0.05), and left ventricular hypertrophy (LVH)
(p = 0.005) were independent predictors of AVR within five years of CABG
surgery. Systemic vascular atherosclerotic disease was a predictor of
rapid disease progression by univariate analysis, and a predictor of
operative mortality by multivariate analysis.
Conclusion: Because of the high mortality associated with repeat operations
within five years, AVR should be considered at the time of CABG in patients
aged £75 years, with a peak transvalvular gradient >30 mmHg, moderately
prominent calcifications with moderately to severely limited valve motion,
and LVH.
The Journal of Heart Valve Disease 2006;15:474-478 |